A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2018
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms STRIDE 3
- Sponsors Kala Pharmaceuticals
- 31 Jul 2018 According to a KALA Pharmaceuticals media release, company has announced the dosing of first patient.
- 31 Jul 2018 Status changed from planning to recruiting.
- 25 Jun 2018 New trial record